This patient is treated for pulmonary arterial hypertension with Adcirca® (tadalafil). The Adcirca® tablets are taken orally at a dose of 40 mg (2 x 20 mg), once a day.

Warning
Concomitant administration of nitrates is contraindicated.
Strongly influences the cytochrome P450 system. On prescription of new medicines this should be taken into account.

Adcirca®
Oval, orange film-coated tablets with 20 mg tadalafil. Tadalafil inhibits phosphodiesterase type 5 (PDE5). Because it relaxes and widens the vessels it improves exercise tolerance, cardiac output and quality of life. Often several medications for pulmonary hypertension are prescribed concomitantly. In case of problems, refer to the product description of all medications to see if they result from medication interaction, side effects or medications effects. Immediately contact the patient's pulmonologist in case of problems.

Side effects
Among others: headache, blush, obstructed nose or frontal sinus, nausea, gastro-intestinal complaints, muscle pain, cloudy view, hypotension, blood nose.